Quick Answer
Amylyx Pharmaceuticals, Inc. reported Total Revenue of $0.00 for the year ending 2025.
- Amylyx Pharmaceuticals, Inc. showed a decrease of -100.0% in Total Revenue from 2024 to 2025.
- This data is from Amylyx Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2021 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $285.0 thousand | Q3 2022: $345.0 thousand | Q3 2022: $345.0 thousand | Q1 2023: $71.43 million | Q2 2023: $98.22 million | Q3 2023: $102.69 million | Q1 2024: $88.64 million | Q2 2024: -$1.02 million | Q3 2024: $416.0 thousand | Q1 2025: $0.00 | Q2 2025: $0.00 | Q3 2025: $0.00.
- Over the full 7 years of available data (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s Total Revenue has declined by 100.0%.
- Historical annual values: Fiscal year 2025: $0.00 | Fiscal year 2024: $87.37 million | Fiscal year 2023: $380.79 million | Fiscal year 2023: $380.79 million | Fiscal year 2022: $22.23 million | Fiscal year 2022: $22.23 million | Fiscal year 2021: $285.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: